BDR Pharma launches new injectable to treat drug resistant infections

Mumbai-based BDR Pharmaceuticals International has announced the launch of XATRONEM-AV (Aztreonam + Avibactam Injection) 2g, an advanced antibacterial therapy developed for the treatment of serious infections caused by multidrug-resistant (MDR) Gram-negative bacteria.

The launch comes at a time when antimicrobial resistance (AMR) is emerging as one of the most pressing global healthcare challenges. Drug-resistant infections are estimated to directly cause nearly 1.9 million deaths annually and are associated with more than 8.2 million deaths worldwide every year. 

The therapy is intended for use in hospitalised patients suffering from severe infections, including complicated intra-abdominal infections, hospital-acquired infections, bloodstream infections, ventilator-associated infections and other serious Gram-negative bacterial infections where conventional therapies may prove ineffective.

Available in a 2g injectable formulation, XATRONEM-AV expands access to advanced antimicrobial therapies for patients battling life-threatening infections, supporting timely and effective treatment of multidrug-resistant Gram-negative infections.